TD Asset Management’s PhaseBio Pharmaceuticals, Inc. Common Stock PHAS Stock Holding History

TD Asset Management’s Portfolio PHAS Stock Details PHAS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-32,443	Closed	-$149K	–	1413
2020 Q2	$149K	Hold	32,443	–	–	﹤0.01%	1302
2020 Q1	$107K	Sell	32,443 -11,400	-26%	-$52.2K	﹤0.01%	1337
2019 Q4	$268K	Buy	43,843 +4,500	+11%	+$18.5K	﹤0.01%	1334
2019 Q3	$164K	Sell	39,343 -1,000	-2%	-$7.97K	﹤0.01%	1314
2019 Q2	$529K	Buy	40,343 +8,555	+27%	+$105K	﹤0.01%	1173
2019 Q1	$302K	Buy	31,788 +600	+2%	+$2.38K	﹤0.01%	1262
2018 Q4	$96K	Buy	+31,188	New	+$124K	﹤0.01%	1378

Other funds holding PHAS

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

JJIJ

Johnson & Johnson Innovation - JJDC New Brunswick, New Jersey $978M AUM 102.17% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

TD Asset Management's PHAS Position: Q3 2020 in Review

TD Asset Management sold out of PhaseBio Pharmaceuticals, Inc. Common Stock (PHAS) in Q3 2020, closing a stake of 32,443 shares — an estimated $149K sold.

TD Asset Management first reported a position in PHAS in Q4 2018 and held it in 7 quarters. The position peaked at $529K in Q2 2019. 50 funds tracked by Wall St. Rank hold PHAS as of Q3 2020.

TD Asset Management reported no remaining PhaseBio Pharmaceuticals, Inc. Common Stock position as of Q3 2020 after selling out during the quarter.
TD Asset Management sold 32,443 PhaseBio Pharmaceuticals, Inc. Common Stock shares in Q3 2020, an estimated $149K.
TD Asset Management first reported a position in PhaseBio Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 7 quarters.
TD Asset Management's PhaseBio Pharmaceuticals, Inc. Common Stock position peaked at $529K in Q2 2019.
50 funds tracked by Wall St. Rank held PhaseBio Pharmaceuticals, Inc. Common Stock as of Q3 2020.

Based on TD Asset Management's 13F filing for Q3 2020, filed 10 Nov 2020.